Curis, Inc. (NASDAQ:CRIS) saw a significant drop in short interest in April. As of April 15th, there was short interest totalling 11,460,000 shares, a drop of 27.2% from the March 31st total of 15,740,000 shares. Based on an average trading volume of 1,960,000 shares, the short-interest ratio is presently 5.8 days.
CRIS has been the topic of a number of recent analyst reports. Zacks Investment Research downgraded Curis from a “hold” rating to a “sell” rating in a research report on Friday, March 19th. B. Riley started coverage on Curis in a research note on Tuesday, March 30th. They issued a “buy” rating and a $19.00 price target for the company. TheStreet raised Curis from a “d-” rating to a “c-” rating in a report on Tuesday, March 23rd. HC Wainwright upped their price objective on shares of Curis from $9.00 to $16.00 and gave the company a “buy” rating in a report on Friday, January 15th. Finally, Jonestrading lifted their target price on shares of Curis from $14.00 to $18.00 and gave the stock a “buy” rating in a research note on Wednesday, March 17th. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $14.17.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Pacer Advisors Inc. acquired a new position in shares of Curis during the 1st quarter worth about $49,000. Captrust Financial Advisors acquired a new position in Curis in the 4th quarter valued at $41,000. Lindbrook Capital LLC purchased a new position in Curis during the 4th quarter worth $57,000. Blair William & Co. IL purchased a new position in Curis during the 4th quarter worth $82,000. Finally, Chicago Partners Investment Group LLC acquired a new stake in shares of Curis in the 1st quarter worth approximately $110,000. Institutional investors and hedge funds own 34.66% of the company’s stock.
Curis (NASDAQ:CRIS) last posted its earnings results on Monday, March 15th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.02). The company had revenue of $3.02 million for the quarter, compared to the consensus estimate of $2.74 million. During the same period in the previous year, the company earned ($0.22) EPS. Research analysts expect that Curis will post -0.62 EPS for the current year.
Curis Company Profile
Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation that is in Phase Ia/Ib clinical trial in patients with solid tumors.
Further Reading: What is Considered a Good Return on Equity (ROE)?
Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.